<DOC>
	<DOCNO>NCT01720069</DOCNO>
	<brief_summary>To evaluate clinical efficacy , safety , tolerability dose-response relationship , use oral corticosteroid ( OCS ) modulation , 3 different dos VR506 use twice daily regimen new dry powder inhaler ( nDPI ) 16 week subject severe persistent asthma require OCS therapy , i.e . Step 5 treatment define modify Global Initiative Asthma ( GINA ) guideline 2011 .</brief_summary>
	<brief_title>Clinical Study Evaluate Efficacy Safety VR506 Using New Inhaler Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion : Written inform consent Adolescents age 1217 year &amp; adult age 1865 year ( inclusive ) Documented clinical history severe asthma require prednisone/prednisolone therapy , highintensity treatment ICS , OCS , LABA Stable OCS dose ≥7 day Screening Visit &amp; Screening Period . At least 80 % compliant w/regular asthma medication per investigator end Screening Period Documented asthma reversibility within 5 yrs prior to/during Screening Period , diagnosis asthma incontrovertible per investigator Ability use nDPI correctly , per investigator 's review complete inhaler operation checklist Ability use eDiary correctly , assess investigator end Screening Period Ability comply w/study procedure , include blood sample Ability perform technically satisfactory pulmonary function test Available complete study visit 12 noon BMI 1626 kg/m2 adolescent 1832 kg/m2 adult Oral PIF ≥40 L/min , use appropriate device set match resistance inhaler Good health , except presence asthma , per medical history/physical examination Negative drug/alcohol/urine cotinine screen . Subjects must test negative amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , cotinine , ethanol &amp; opiate ( unless give prescription medicine ) Nonsmokers exsmokers smoke history le 10 packyrs ( e.g . &lt; 20 cigarette per day 10 year &lt; 40 cigarette per day 5 year ) &amp; stop smoke least 1 year prior Screening Visit . Smoking permit throughout study Female subject childbearing potential must use medically acceptable form contraception [ abstinence , hormonal ( oral/implant/transdermal/injection ) , use ≥3 consecutive month first dose study medication , double barrier ( condom w/spermicide , diaphragm w/spermicide ) , IUD , vasectomise partner ( ≥6 month since vasectomy ) ] . Exclusion : Regular use ( ≥3 times/wk ) topical steroid treat dermatitis/rhinitis/allergic conjunctivitis , within 28 day Screening Visit Subjects have/who , upper/lower respiratory tract infection within 28 day Screening Visit Subjects w/ '' brittle asthma Subjects w/asthma require admission ICU and/or ventilation within previous 12 month Subjects whose comorbidities , per investigator 's opinion , major contributor respiratory symptom ( e.g . COPD , bronchiectasis , dysfunctional breathlessness , vocal cord dysfunction , gastrooesophageal reflux ) Previously/currently diagnose ChurgStrauss syndrome Previously/currently diagnose pulmonary eosinophilia History lung cancer Subjects w/current diagnosis HIV infection Active chronic hepatitis B C infection Subjects clinically significant abnormality/finding examination , test , history may compromise subject safety , specifically history cardiac , renal hepatic impairment Subjects abnormal ECG Persistent arterial hypotension , average SBP reading ≤95 mmHg Persistent elevation blood pressure , average SBP reading ≥160 mmHg average DBP read ≥100 mmHg Pregnant lactating female Participation another clinical study 28 day prior Screening Visit Evidence clinically significant renal , hepatic , cardiac , pulmonary ( apart asthma ) metabolic dysfunction , e.g . diabetes mellitus , thyrotoxicosis , uncorrectable hypokalaemia , predisposition low level serum potassium Current/history drug/alcohol abuse/dependence per WHO criteria Inability communicate well w/investigator Donation ≥450 mL blood/blood product within previous 3 month prior screen History allergy/intolerance/contraindications corticosteroids/lactose , severe allergy milk proteins Consumption alcohol caffeinecontaining foods/beverages midnight Screening Visit History medically diagnose chronic respiratory disease asthma ( e.g . chronic obstructive pulmonary disease , ABPA absence asthma )</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>